Project

Mouse Acute Promyelocytic Leukemia (APL) as a model for Acute Myeloid Leukemia (AML) (CIP)

This project will sequence the genomes of APL tumors arising in a well-defined mouse model, define recurring mutations in a set of mouse APL tumors, and compare these mutations to those found in human APL tumors.

Mouse Acute Promyelocytic Leukemia (APL) as a model for Acute Myeloid Leukemia (AML) (CIP) Details

Center Initiated Projects (CIPs) are proposed by the McDonnell Genome Institute to help fulfill the mission and strategic vision of the NHGRI and NIH. All CIP data will be released in a timely manner via appropriate databases in accordance with NHGRI and NIH guidelines.

Project Summary: Recurring mutations found in mouse APL genomes, if also found in human AML genomes, are extremely likely to be relevant for disease pathogenesis. Sequencing mouse cancer genomes arising in inbred strains requires much less sequence coverage (~1/6) than human AML genomes, reducing the cost and time to discovery of potentially relevant mutations. We will therefore sequence the genomes of 14 APL tumors arising in a well-defined mouse model, define recurring mutations in a set of 94 mouse APL tumors, and compare these mutations to those found in human APL tumors. This data may have broader relevance, since many progression mutations found in human AML are relevant for other cancers (e.g. activating Ras and tyrosine kinase receptor mutations). Status of Samples: 14 samples in house for whole genome sequencing and custom capture. All samples are currently in analysis. Follow-up work will include validation and extension sequencing. Collaborators: Dr. Tim Ley. IRB Status: not applicable (non-human sequencing).